原发性乳腺弥漫大B细胞淋巴瘤研究进展  

Research progress of primary breast diffuse large B cell lymphoma

作　　者：李基炜 易平勇[1] 

机构地区：[1]中南大学湘雅医学院附属肿瘤医院淋巴瘤,血液内科,长沙410000

出　　处：《中国医师杂志》2016年第7期1114-1117,共4页Journal of Chinese Physician

摘　　要：原发性乳腺恶性淋巴瘤是一种罕见的结外非霍奇金淋巴瘤，以乳腺肿块为主要症状，伴或不伴局部淋巴结肿大，易转移、预后差，最常见的病理类型是原发性弥漫大B细胞淋巴瘤（PB-DLBCL），滤泡淋巴瘤等其他病理类型较少见。原发性弥漫大B细胞淋巴瘤的预后因素及一线治疗方案尚未达成共识。本文将主要描述原发性乳腺弥漫大B细胞淋巴瘤的发病机制、分期、风险分层、预后及最新治疗进展。Primary breast lymphoma （PBL） is a rare form of extranodal non-Hodgkin lymphoma, with breast mass as the main symptom,with or without local lymphadenpathy, and it shows metastatic features and poor prognosis. Diffuse large B-cell lymphoma is the must common pathological pattern, other forms like follicular lymphoma is less common. There is no consensus on prognostic factor and first-line treatment plan at present. In this review,we describe the pathogenesis, staging, risk stratification, prognosis, and treatment advances of primary breast diffuse large B cell lymphoma （PB-DLBCL）.

关 键 词：淋巴瘤 大B细胞 弥漫性 乳腺肿瘤 综述 

分 类 号：R737.9[医药卫生—肿瘤]